2231-3915 (Online)
2231-3907 (Print)

Author(s): Amber Vyas, Vishal Jain


DOI: 10.52711/2231-3915.2023.00010   

Address: Amber Vyas, Vishal Jain
University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, C.G.
*Corresponding Author

Published In:   Volume - 13,      Issue - 2,     Year - 2023

Background: Dermatophytic infections, primarily affecting keratinized tissues such as skin, hair, and nails, pose significant therapeutic challenges. Luliconazole, a novel imidazole antifungal agent, has garnered attention for its efficacy against these infections. This review article aims to synthesize current knowledge on luliconazole, focusing on its chemical properties, mechanism of action, clinical efficacy, and application in treating dermatophytoses. Methods: A comprehensive review of recent studies and clinical trials involving luliconazole was conducted. Key focus areas included its antifungal spectrum, particularly against dermatophytes like Trichophyton rubrum, Microsporum gypseum, and Epidermophyton floccosum, and its pharmacokinetic properties that contribute to its effectiveness in treating dermatophytic infections. Results: Luliconazole exhibits potent activity against filamentous fungi, including dermatophytes. It interferes with ergosterol synthesis in fungal cell membranes, leading to increased membrane permeability and cell death. Formulated as a 1% topical cream and a 10% solution, luliconazole has shown significant efficacy in treating conditions such as tinea pedis, tinea cruris, and onychomycosis. Clinical studies demonstrate luliconazole's superiority over other antifungals like clotrimazole, with higher cure rates and rapid symptom resolution. Furthermore, its unique molecular structure enhances penetration into the nail plate, making it effective against onychomycosis. Conclusion: Luliconazole represents a significant advancement in antifungal therapy, offering a potent and targeted option for dermatophytosis treatment. Its broad-spectrum activity, combined with favorable pharmacokinetic properties, underscores its potential as a first-line treatment for various dermatophyte-related infections. Future research should focus on long-term efficacy, resistance patterns, and potential systemic applications of luliconazole.

Cite this article:
Amber Vyas, Vishal Jain. Luliconazole promising drug for Dermatophytes: A Review. International Journal of Technology. 2023; 13(2):79-4 doi: 10.52711/2231-3915.2023.00010

Amber Vyas, Vishal Jain. Luliconazole promising drug for Dermatophytes: A Review. International Journal of Technology. 2023; 13(2):79-4 doi: 10.52711/2231-3915.2023.00010   Available on:

1.    Shokri A, Abastabar M, Keighobadi M, et al. Promising antileishmanial activity of novel imidazole antifungal drug luliconazole against Leishmania major: In vitro and in silico studies. J Glob Antimicrob Resist. Sep 2018;14:260-265. doi:10.1016/j.jgar.2018.05.007
2.    Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core evidence. 2014;9:113-24. doi:10.2147/ce.S49629
3.    Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. Jul 2014;57(7):389-93. doi:10.1111/myc.12168
4.    Dakhale GN, Gupta AV, Mukhi JI, Kalikar MVJPiCR. Comparison of efficacy, safety, and cost-effectiveness of sertaconazole and luliconazole cream in patients with dermatophytoses: A prospective, randomized, open-label study. 2021;12(4):223.
5.    Feng X, Xie J, Zhuang K, Ran YJTJoD. Efficacy and tolerability of luliconazole cream 1% for dermatophytoses: A Meta‐analysis. 2014; 41(9): 779-782.
6.    AL-Khikani FHOJB, Journal BR. Dermatophytosis a worldwide contiguous fungal infection: Growing challenge and few solutions. 2020;4(2):117-122.
7.    Almeida SRJM. Immunology of Dermatophytosis. 2008;166(5-6):277-283.
8.    Moriello KA, Coyner K. Dermatophytosis. Greene's Infectious Diseases of the Dog and Cat. Elsevier; 2021:961-977.
9.    Pires CAA, Cruz NFSd, Lobato AM, Sousa POd, Carneiro FRO, Mendes AMDJAbdd. Clinical, epidemiological, and therapeutic profile of dermatophytosis. 2014;89:259-264.
10.    Sohnle PG. Dermatophytosis. Immunology of the Fungal Diseases. crc Press; 2020:1-27.
11.    AL-Khikani FH, Ayit ASJEJoD, Venerology. Major challenges in dermatophytosis treatment: current options and future visions. 2021;41(1):1-9.
12.    Kansagra H, Mallick SJJoPI. Microemulsion-based antifungal gel of luliconazole for dermatophyte infections: formulation, characterization and efficacy studies. 2016;46:21-28.
13.    Degreef HJM. Clinical forms of dermatophytosis (ringworm infection). 2008;166(5-6):257-265.
14.    Kaur M, Gupta A, Mahajan R, Gill MJIJoA, Research BM. Efficacy, safety, and cost evaluation of the topical luliconazole therapy versus topical clotrimazole therapy in patients with localized dermatophytosis in a tertiary care hospital: An observational study. 2020;10(4):260.
15.    Vermout S, Tabart J, Baldo A, Mathy A, Losson B, Mignon BJM. Pathogenesis of dermatophytosis. 2008;166:267-275.
16.    Saunders J, Maki K, Koski R, Nybo SEJJopp. Tavaborole, efinaconazole, and luliconazole: three new antimycotic agents for the treatment of dermatophytic fungi. 2017;30(6):621-630.
17.    Baghel S, Nair VS, Pirani A, et al. Luliconazole‐loaded nanostructured lipid carriers for topical treatment of superficial Tinea infections. 2020;33(6):e13959.
18.    Baghi N, Shokohi T, Badali H, et al. In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. 2016;54(7):757-763.
19.    Koga H, Tsuji Y, Inoue K, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. 2006;12(3):163-165.
20.    Gnat S, Dyląg M, Łagowski D, Zielinski JJM. Therapeutic efficacy of topically used luliconazole vs. terbinafine 1% creams. 2021;64(8):967-975.
21.    Shah MJ. Comparative Study of Efficacy and Safety of Topical Luliconazole (1%) Versus Topical Terbinafine (1%) in Treatment of Tinea Corporis/Cruris. Rajiv Gandhi University of Health Sciences (India); 2018.
22.    Koga H, Nanjoh Y, Kaneda H, Yamaguchi H, Tsuboi RJAa, chemotherapy. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. 2012;56(6):3138-3143.
23.    Begum J, Mir NA, Lingaraju MC, Buyamayum B, Dev KJJobm. Recent advances in the diagnosis of dermatophytosis. 2020;60(4):293-303.
24.    Lakshmi Prabha M. Efficacy and Safety of Luliconazole (1%) Cream Versus Clotrimazole (1%) Cream in Tinea Infections of Skin: A Comparative Study. Tirunelveli Medical College, Tirunelveli; 2017.
25.    Scher RK, Nakamura N, Tavakkol AJM. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. 2014;57(7):389-393.
26.    Rana DK, Shah TS, Rohit MH, et al. Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis: A randomised control trial. 2024;67(1):e13681.
27.    Nakamura A, Hirakawa S, Nagai H, Inagaki KJMM. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. 2021;59(3):289-295.

Recomonded Articles:

International Journal of Technology (IJT) is an international, peer-reviewed journal, research journal aiming at promoting and publishing original high quality research in all disciplines of engineering sciences and technology...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231-3915 

Recent Articles